Bristol-Myers Squibb Co vs VanEck JP Morgan EM Local Currency Bond ETF — how do they compare? Bristol-Myers Squibb Co trades at $64.69 (market cap $130.12B), while VanEck JP Morgan EM Local Currency Bond ETF trades at $25.65. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while VanEck JP Morgan EM Local Currency Bond ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals.
| BMY | EMLC | |
|---|---|---|
Market Cap | $130.12B | — |
Sector | Health | Fixed Income |
52-Week High | $65.89 | $26.59 |
52-Week Low | $42.60 | $24.83 |
Enterprise Value | $164.11B | — |
Dividend Yield | 3.96% | — |
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →